Skip to main content
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. — Investor Relations & Filings

Ticker · SCNI ISIN · US09073Q3039 US Manufacturing
Open in API
Filings indexed 469 across all filing types
Latest filing 2026-06-08 Proxy Solicitation & In…
Country US United States of America
Listing US SCNI

About Scinai Immunotherapeutics Ltd.

https://www.scinai.com/

Scinai Immunotherapeutics Ltd. is a clinical-stage biopharmaceutical company operating through two complementary business units. Its internal research and development division focuses on developing innovative biological products for inflammation and immunology (I&I), targeting autoimmune and infectious diseases. The core of its therapeutic pipeline is a platform of Alpaca-derived nanosized antibodies (NanoAbs or VHH-antibodies), developed for conditions such as psoriasis and asthma. The company's second unit, Scinai Bioservices, is a Contract Development and Manufacturing Organization (CDMO). It provides end-to-end services to biotech companies, supporting drug development from early research and process development through to cGMP-compliant manufacturing for clinical trials up to Phase 3.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Proxy Solicitation & Information Statement Classification · 82% confidence The document is an SEC Form 6-K filed by a foreign private issuer that furnishes a Notice and Proxy Statement for the upcoming Annual General Meeting of Shareholders and clarifies Proposal No. 6 therein. This is a proxy solicitation/information disclosure to shareholders ahead of the meeting, matching the Proxy Solicitation & Information Statement category.
2026-06-08 English
PROSPECTUS
Share Issue/Capital Change Classification · 85% confidence The document is a Form 424B3 prospectus relating to the resale of American Depositary Shares (ADSs) and warrants. It is an SEC filing regarding a share offering (resale registration) and outlines share issuance terms, warrant exercises and capital structure changes. It is not an Annual Report, earnings release, or simple report publication announcement but a securities offering prospectus. This fits the “Share Issue/Capital Change” category.
2026-05-19 English
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Regulatory Filings Classification · 88% confidence The document is a Form 6-K filing by a foreign private issuer pursuant to the Securities Exchange Act, primarily furnishing a notice and proxy statement and proxy card for its annual meeting. It does not itself contain the proxy materials but references them as exhibits. Under our taxonomy, this is a general regulatory announcement (SEC Form 6-K) rather than the actual proxy statement (PSI). It therefore falls into the Regulatory Filings (RNS) category.
2026-05-12 English
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Regulatory Filings Classification · 85% confidence The document is a Form 6-K (current report of a foreign private issuer) filed pursuant to the Securities Exchange Act. It furnishes exhibits (audited subsidiary financials and unaudited pro forma financial information) under Rule 13a-16/15d-16. There is no substantive narrative or full financial statements beyond the exhibits, and it serves as a regulatory submission. This falls under the catch-all Regulatory Filings category (RNS).
2026-05-08 English
6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Scinai Immunotherapeutics Ltd., with the SEC. It reports a private placement financing transaction including issuance of American Depositary Shares (ADSs), warrants, and related agreements. The document details the terms of the securities purchase agreement, registration rights agreement, warrant inducement, and compensation to financial advisors. It includes exhibits with forms of warrants and agreements. The document is not an annual or quarterly report, audit report, earnings release, or management discussion. It is a regulatory filing reporting a capital raising event and related agreements. The document length is over 11,000 characters and contains substantive details about the financing transaction. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-04-27 English
20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)
Annual Report FY 2025
2026-04-01 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.